"Endometrial Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of ENDOMETRIUM, the mucous lining of the UTERUS. These neoplasms can be benign or malignant. Their classification and grading are based on the various cell types and the percent of undifferentiated cells.
| Descriptor ID |
D016889
|
| MeSH Number(s) |
C04.588.945.418.948.585 C13.351.500.852.762.200 C13.351.937.418.875.200
|
| Concept/Terms |
Endometrial Neoplasms- Endometrial Neoplasms
- Endometrial Neoplasm
- Neoplasm, Endometrial
- Neoplasms, Endometrial
Endometrial Carcinoma- Endometrial Carcinoma
- Carcinoma, Endometrial
- Carcinomas, Endometrial
- Endometrial Carcinomas
- Endometrial Cancer
- Cancer, Endometrial
- Cancers, Endometrial
- Endometrial Cancers
- Endometrium Cancer
- Cancer, Endometrium
- Cancers, Endometrium
- Cancer of the Endometrium
- Carcinoma of Endometrium
- Endometrium Carcinoma
- Endometrium Carcinomas
- Cancer of Endometrium
- Endometrium Cancers
|
Below are MeSH descriptors whose meaning is more general than "Endometrial Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Endometrial Neoplasms".
This graph shows the total number of publications written about "Endometrial Neoplasms" by people in this website by year, and whether "Endometrial Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 2 | 2 | 4 |
| 1997 | 1 | 0 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 0 | 2 |
| 2000 | 1 | 0 | 1 |
| 2001 | 4 | 0 | 4 |
| 2002 | 3 | 0 | 3 |
| 2003 | 2 | 0 | 2 |
| 2004 | 2 | 0 | 2 |
| 2005 | 3 | 0 | 3 |
| 2006 | 3 | 0 | 3 |
| 2007 | 5 | 0 | 5 |
| 2008 | 5 | 0 | 5 |
| 2009 | 6 | 0 | 6 |
| 2010 | 4 | 0 | 4 |
| 2011 | 5 | 0 | 5 |
| 2012 | 9 | 0 | 9 |
| 2013 | 7 | 0 | 7 |
| 2014 | 6 | 0 | 6 |
| 2015 | 10 | 0 | 10 |
| 2016 | 4 | 0 | 4 |
| 2017 | 12 | 0 | 12 |
| 2018 | 6 | 0 | 6 |
| 2019 | 7 | 0 | 7 |
| 2020 | 5 | 0 | 5 |
| 2021 | 4 | 0 | 4 |
| 2022 | 8 | 0 | 8 |
| 2023 | 1 | 0 | 1 |
| 2024 | 5 | 0 | 5 |
To return to the timeline,
click here.
Below are the most recent publications written about "Endometrial Neoplasms" by people in Profiles.
-
Oklahoma nitrone-007 is an effective anticancer therapeutic agent targeting inflammatory and immune metabolism pathways in endometrial cancer. J Pharmacol Exp Ther. 2025 Jan; 392(1):100004.
-
ENGOT-EN20/GOG-3083/XPORT-EC-042 - A phase III, randomized, placebo-controlled, double-blind, multicenter trial of selinexor in maintenance therapy after systemic therapy for patients with p53 wild-type, advanced, or recurrent endometrial carcinoma: rationale, methods, and trial design. Int J Gynecol Cancer. 2024 Aug 05; 34(8):1283-1289.
-
Overall survival in patients with endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel in the randomized ENGOT-EN6/GOG-3031/RUBY trial. Ann Oncol. 2024 Aug; 35(8):728-738.
-
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study. Gynecol Oncol. 2024 06; 185:202-211.
-
Radiation Therapy With or Without Cisplatin for Local Recurrences of Endometrial Cancer: Results From an NRG Oncology/GOG Prospective Randomized Multicenter Clinical Trial. J Clin Oncol. 2024 Jul 10; 42(20):2425-2435.
-
Niclosamide causes lysosome-dependent cell death in endometrial cancer cells and tumors. Biomed Pharmacother. 2023 May; 161:114422.
-
Identification of Candidate Biomarker and Drug Targets for Improving Endometrial Cancer Racial Disparities. Int J Mol Sci. 2022 Jul 14; 23(14).
-
Hysterectomy with a general gynecologist vs gynecologic-oncologist in the setting of endometrial intraepithelial neoplasia: a cost-effectiveness analysis. Am J Obstet Gynecol. 2022 10; 227(4):609.e1-609.e8.
-
Conditional estimates for uterine serous cancer: Tools for survivorship counseling and planning. Gynecol Oncol. 2022 07; 166(1):90-99.
-
A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium. Gynecol Oncol. 2022 07; 166(1):44-49.